Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College & Honorary Consultant Physician at Royal Brompton Hospital, London. Has been the most highly cited clinical scientist in Europe & the most highly cited respiratory researcher in the world over the last 20 years. Elected a Fellow of the Royal Society in 2007. Currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD).
Barnes is the author of over 1,000 publications in peer reviewed journals. He has edited or co-edited over 50 books on asthma, COPD and respiratory pharmacology.
He has been received honorary degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland), Leuven (Belgium) and Maastricht (Netherlands). He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Professor of Pulmonary Medicine at the Univeristy of Montpellier. Former Director of the INSERM Laboratory for the Immunopathology of Asthma & former chairman of the Global Initiative for Asthma (GINA). Founder & Chairman of ARIA (Allergic Rhinitis & its Impact on Asthma). Chairman of the WHO Global Alliance against Chronic Respiratory Diseases (GARD). Former President of the Societé Française d'Allergologie et d'Immunologie Clinique. Former EiC of the journal Allergy.
Professor and Chairman, Department of Genetic Medicine, and Bruce Webster Professor of Internal Medicine, at Weill Cornell Medical College. Director of the Belfer Gene Therapy Core Facility. Attending Physician at the Weill Cornell-New York Presbyterian Hospital. Previously, Chief of Pulmonary Branch, NHLBI, NIH.
Assistant Professor of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine.
Burton F. Dickey is a Professor and Chair of the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center. He has studied vesicle traffic since fellowship training more than thirty years ago, and for the past seventeen years his principal focus has been airway mucin secretion. His laboratory uses a mouse genetic approach, knocking out or overexpressing genes in airway secretory cells to study their function. This approach also allows the use of these genetically modified mice in models of pathologic challenge. Together, this provides fundamental insight into the mechanism of mucin secretion and how its dysregulation contributes to pathophysiology. He has also contributed to related work on inducible epithelial resistance to infection, promotion of lung carcinogenesis by inflammation, and modulation of inflammation by β2-agonists. As a clinician, Dr. Dickey focuses on diseases of the airways to promote the transfer of knowledge between laboratory and clinic. He has founded two biotechnology companies, Pulmotect and Exotect, to develop therapeutics to treat respiratory infections and muco-obstructive lung diseases, respectively.
Delia Goletti MD, PhD, Infectious Diseases specialist. In 1992 she joined the Laboratory of Immunoregulation at the National Institutes of Health (chief Dr Fauci) working on HIV pathogenesis. In 1999 she joined the National Institute for Infectious Diseases in Rome. She has clinical duties on the tuberculosis (TB) clinic and responsibility of the Translational Research Unit where she works on TB pathogenesis, TB immunodiagnostic tests and impact of Heminths infection on HIV and TB disease.
Consulting biostatistician in the Division of Health Sciences at the University of Otago. In this role, I provide biostatistical expertise to a wide range of researchers on a large number of projects. Much of this is through collaborative relationships as a co-investigator with the remainder through more informal consulting relationships. I have particular interests in obesity research, especially in pediatric populations; nuts as a functional food; respiratory epidemiology; and sun protection. Prior to my current position I was a software metrics and machine learning researcher in the Department of Information Science at the same institution.
Keith Klugman, director for pneumonia, leads the Bill & Melinda Gates Foundation’s work to improve the development and delivery of pneumonia vaccines and expand the use of antibiotic treatments and diagnostic tools.
Keith is a leading expert on antibiotic resistance in pneumonia pathogens and helped develop the pneumococcal vaccine that is now part of the immunization regimen for children born in the United States and is being rolled out globally. Keith was the William H. Foege Professor of Global Health and Professor of Epidemiology in the Rollins School of Public Health at Emory University as well as Professor of Medicine in the Division of Infectious Diseases at the Emory School of Medicine. In addition, he still serves as Honorary Professor in the Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand in South Africa.
Keith has chaired or served on numerous expert committees for the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), among other American and international organizations, and has published more than 450 scientific papers on the subjects of pneumonia, meningitis, antimicrobial resistance, and vaccines for bacterial pathogens, which have been cited more than 20,000 times to date. He is currently the President of the International Society for Infectious Diseases.
Keith trained in South Africa and did his post-doctoral research at Rockefeller University in New York.
Main research Interests:
A) Asthma is a major cause of morbidity in the Western world but curative therapies do not exist. Hence, we aim to understand how early life environmental exposures modify lung development development and the risk of developing asthma throughout life. We use animal models of prenatal exposure to tobacco/nicotine products and human samples.
B) The importance of a steady-state balance of resident and non-resident bacterial communities for human health is increasingly appreciated. Yet, factors driving the composition of such microbial communities remain poorly understood. Therefore, we currently investigate the influence of smoke on the structure and functionality of the lung microbiome and its interaction with the lung health.
Currently Funded Projects
2012 – 2016 Chair of COST Action BM1201 “Developmental origins of Chronic Lung Disease” http://www.cost-early-origin-cld.eu/
2013 – 2016 Understanding the role of the lung microbiome for human health and diseases”, HMGU Environmental Health Projects, Co-PI until move to University of Kiel; Project currently continued on a collaborative basis.
Since 2013 – 2018 PI within German Center for Lung Research www.dzl.de
2016 - 2018 Chair of “The lung Microbiota at the Interface between airway epithelium and the environment” funded by the Leibniz Association
The Representative Director, Kyoto Industrial Health Association
Chair Professor, Ritsumeikan University
I am a Computational Biologist, Assistant Professor at Weill Medical College of Cornell University. I use -omic data to understand the mechanisms of disease risk.
I began my career as a Biology Undergraduate at MIT, where my first research project was to invent a method for attaching DNA to glass as part of the then-unfinished Human Genome Project. After MIT, I explored career options in Medical School Sillicon Valley and NIH, eventually earning a PhD in Bioinformatics and Systems Biology from UCSD. My doctoral dissertation involved characterizing the regulatory genetics of the adrenaline-synthesis gene PNMT, as well as more broadly studying the human adrenergic stress pathway. Seeking additional training in genomics and statistics, I spent a year working with Kelly Frazer at the Moores UCSD Cancer Center, followed by a move to Weill Cornell Medical College in 2010. As a postdoc, I developed a set of genomic analysis skills and tools that I applied to numerous projects, both locally and with international collaborators such as the 1000 Genomes Project, Weill Cornell Medical School in Qatar, and the University of Puerto Rico. In my current appointment as Assistant Professor, I am tasked with developing biotechnology tools for precision medicine.